Broker's call: Zydus Lifesciences (Accumulate)

Zydus Lifesciences' Q4 earnings surprised analysts, with higher sales in key markets like the US and India driving growth. The company is developing new products, but "timely launch will be key to sustaining momentum." Experts suggest accumulating the stock, setting a target price of ₹1,080.